

Tier 1 Pharmaceutical Manufacturer Selects Kneat's SaaS platform

February 15, 2018 1:00 PM EST

HALIFAX, February 15, 2018/CNW/ – kneat.com, inc. (TSX-V: KSI) ("kneat.com", "Kneat", or the "Company") is pleased to announce that a leading Tier 1 pharmaceutical company, headquartered in the United States and with over thirty manufacturing and laboratory sites globally, has selected Kneat. Kneat's software platform will replace the client's paper-based commissioning and qualification ("C&Q") process with one that is end-to-end paperless. Our new client is seeking to improve data integrity and productivity by implementing a structured C&Q process that can be leveraged globally across all sites. The desired outcome is to enable:

- users to be more compliant and productive in real-time as they perform their work;
- · managers full central visibility and control across all projects and systems; and
- senior management to enhance compliance and drive down operational and capital costs.

The initial deployment is for C&Q at the client's headquartered manufacturing site in the United States, with deployment commencing immediately on Kneat's Software as a Service ('SaaS') platform.

"We are proud that this multinational pharmaceutical company recognizes the benefits of our software and we look forward to deployment in the near future." said Eddie Ryan, CEO of Kneat.

Kneat continues to expand its customer pipeline and will report on further developments as they occur.

About Kneat

Kneat, headquartered in Limerick, Ireland, develops and markets the next generation Kneat Gx software platform. Kneat Gx, enables an end-to-end paperless process for all validations, commissioning and qualification, production execution and quality document management. Kneat Gx allows users to electronically create, approve and execute all deliverables, manage any exceptions and post approve final deliverables in a controlled FDA Part 11/ Eudralex Annex 11 compliant platform. Users with correct permissions can see everything in real time. Customer case studies are reporting productivity improvements in excess of 100% and a higher compliance standard. www.kneat.com.

Cautionary and Forward-Looking Statements

Except for the statements of historical fact contained herein, certain information presented constitutes "forward-looking information" within the meaning of applicable Canadian securities laws. Such forward-looking information, includes, but is not limited to, the ability to generate sales of the Kneat Gx platform, the ability to build relationships with current and prospective customers, the market potential for the Kneat Gx platform, the ability to develop new features for the Kneat Gx platform, and the compliance of the Kneat Gx platform under regulatory audit and inspection. While such forward-looking statements are expressed by the Company, as stated in this release, in good faith and believed by the Company to have a reasonable basis, they are subject to important risks and uncertainties. As a result of these risks and uncertainties, the events predicted in these forward-looking statements may differ materially from actual results or events. These forward-looking statements are not guarantees of future performance, given that they involve risks and uncertainties. The Company does not undertake any obligation to release publicly revisions to any forward-looking statement, except as may be required under applicable securities laws. Investors should not assume that any lack of update to a previously issued forward-looking statement constitutes a reaffirmation of that statement. Continued reliance on forward-looking statements is at an investor's own risk.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information: Sarah Oliver, CFO, kneat.com, inc., 2001-1969 Upper Water Street, Halifax, NS, B3J 3R7, T: +353 61 203826, E: inquiry@kneat.com